<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Asia Pac Allergy</journal-id><journal-id journal-id-type="publisher-id">APA</journal-id><journal-title-group><journal-title>Asia Pacific Allergy</journal-title></journal-title-group><issn pub-type="ppub">2233-8276</issn><issn pub-type="epub">2233-8268</issn><publisher><publisher-name>Asia Pacific Association of Allergy, Asthma and Clinical Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3206230</article-id><article-id pub-id-type="pmid">22053290</article-id><article-id pub-id-type="doi">10.5415/apallergy.2011.1.1.2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Current Review</subject></subj-group></article-categories><title-group><article-title>Clinical applications of drug desensitization in the Asia-Pacific region</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Thong</surname><given-names>Bernard Yu-Hor</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 308433, Republic of Singapore.</aff><author-notes><corresp>
Correspondence: Bernard Yu-Hor Thong. Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Republic of Singapore. Tel: +65-6357-7822, Fax: +65-6357-7837, <email>bernard_thong@ttsh.com.sg</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2011</year></pub-date><volume>1</volume><issue>1</issue><fpage>2</fpage><lpage>11</lpage><history><date date-type="received"><day>19</day><month>3</month><year>2011</year></date><date date-type="accepted"><day>09</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Drug desensitization is the induction, within hours to days, of a temporary state of tolerance to a drug which the patient has developed a hypersensitivity reaction to. It may be used for IgE and non-IgE mediated allergic reactions, and certain non-allergic reactions. The indication for desensitization is where no alternative medications are available for the treatment of that condition, and where the benefits of desensitization outweigh the risks. Desensitization is a therapeutic modality for drug allergy (similar to allergen specific immunotherapy for allergic rhinitis and insect venom anaphylaxis). In contrast, the drug provocation test is a diagnostic modality used to confirm or refute the diagnosis of drug allergy. This review discusses the clinical applications of desensitization for the treatment of common infectious, metabolic and cardiovascular diseases, and oncological conditions in the Asia-Pacific region.</p></abstract><kwd-group><kwd>Anaphylaxis</kwd><kwd>Desensitization</kwd><kwd>Drug hypersensitivity</kwd><kwd>Stevens Johnson syndrome</kwd><kwd>Toxic epidermal necrolysis</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Although many classes of drugs are presently available to treat various medical conditions, certain drugs with the potential to cause allergic or non-allergic drug hypersensitivity reactions [<xref ref-type="bibr" rid="B1">1</xref>] may be the therapeutic drug of choice as no better alternatives are available. Examples of drugs with a propensity to cause drug allergy include isoniazid, rifampicin and pyrazinamide for the first-line treatment of tuberculosis (TB); allopurinol for the treatment of tophaceous gout, and trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment and prophylaxis of <italic>Pneumocystis jiroveci</italic> infection and toxoplasmosis in human immunodeficiency virus (HIV) infected patients [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. As for drugs causing non-allergic drug hypersensitivity, aspirin remains an important anti-platelet agent in those with cardiovascular diseases, in particular individuals with coronary artery disease following percutaneous coronary intervention to prevent instent thrombosis.</p><p>Drug desensitization is the induction, within hours to days, of a temporary state of tolerance to a drug which the patient has developed a hypersensitivity reaction to [<xref ref-type="bibr" rid="B4">4</xref>]. Although in the strictest sense, this term/procedure should only be applied to tolerance induction in IgE-mediated allergic drug hypersensitivity, it is now also used in tolerance induction for non-IgE mediated allergic reactions (e.g. non-immediate reactions like maculopapular exanthema and fixed drug eruptions), and non-allergic reactions (e.g. aspirin intolerance or hypersensitivity). The indication for drug desensitization is where no better alternative medications are available for treatment of that condition, and where the benefits of desensitization outweigh the risks. Desensitization is a therapeutic modality for probable or definite drug allergy based on the results of validated allergological tests or drug imputability (similar to specific immunotherapy for allergic rhinitis and insect venom anaphylaxis) [<xref ref-type="bibr" rid="B5">5</xref>]. In contrast, the drug provocation test is a diagnostic modality used to confirm or refute the diagnosis of drug allergy [<xref ref-type="bibr" rid="B6">6</xref>].</p><sec><title>Mechanisms in drug desensitization</title><p>Various studies have proposed different mechanisms for IgE-mediated desensitization: internalization of antigen/IgE/FC&#x003b5;RI and cross-linking of inhibitory receptors on mast cells [<xref ref-type="bibr" rid="B7">7</xref>]; reduced levels of up-stream signal transducing molecules, such as Syk which are necessary for activation and mast cell IgE-signalling [<xref ref-type="bibr" rid="B8">8</xref>]; negative regulation of IgE mediated allergic responses by Lyn kinase in mast cell responses both <italic>in vivo</italic> and <italic>in vitro</italic> [<xref ref-type="bibr" rid="B9">9</xref>]; and elevated levels of the signal transducer and transcriptor activator STAT-6 involved in transcription of IL-4 and IL-13 necessary for desensitization of murine mast cells [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>].</p><p>The mechanism for desensitization in non-immediate reactions remains unknown. This is because of the many mechanisms involved in non-immediate reactions prior to T cell activation, including haptenation, biotransformation of inert prohaptens to reactive haptens [<xref ref-type="bibr" rid="B12">12</xref>], and direct interaction of non-haptens with T-cell receptors [<xref ref-type="bibr" rid="B13">13</xref>]. For instance, interference with SMX haptenation, but not SMX-specific antibodies, appear to be important in the development of clinical sensitivity (i.e. failure of desensitization) in patients with AIDS who have undergone SMX desensitization [<xref ref-type="bibr" rid="B14">14</xref>]. At the site of the target organ, CD25+CD4+ T regulatory cells in the epidermis of lesions of fixed drug eruptions (FDE) appear to be important in the induction of desensitization to allopurinol FDE [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>In non-allergic drug hypersensitivity reactions like acetylsalicylic acid (ASA) or aspirin intolerance, abnormal metabolism of arachidonic acid results in a decrease in the levels of the anti-inflammatory prostaglandins, especially prostaglandin E2, and an increase in the synthesis of cysteinyl leukotrienes, particularly leukotrienes C4, D4 and E4. The excessive production of leukotrienes results in urticaria, angioedema, bronchospasm and occasionally non-allergic anaphylactic (anaphylactoid) reactions in such pre-disposed individuals [<xref ref-type="bibr" rid="B16">16</xref>]. These patients often develop aspirin exacerbated respiratory disease (AERD) which comprises aspirin intolerant asthma with chronic rhinosinusitis and/or nasal polyposis, or aspirin induced urticaria (AIU)/ aspirin-exacerbated chronic urticaria [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>]. High dose aspirin desensitization (650-1,300 mg/day) has been shown to ameliorate AERD symptoms through various postulated mechanisms including direct mast cell inhibition [<xref ref-type="bibr" rid="B19">19</xref>], direct modulation of the intracellular biochemical pathways of inflammatory cells, reduced production of thromboxane A2, reduced leukotriene B4 levels [<xref ref-type="bibr" rid="B20">20</xref>], increased LTE4 levels [<xref ref-type="bibr" rid="B21">21</xref>], inhibition of activation of transcription factors like NF&#x003ba;B [<xref ref-type="bibr" rid="B22">22</xref>], and inhibition of IL-4 and IL-13 induced activation of STAT6 [<xref ref-type="bibr" rid="B23">23</xref>]. During acute desensitization in AERD, significant elevation in exhaled nitric oxide and serum tryptase levels have been demonstrated; in long term treatment with ASA, IL-4 is suppressed, the pro-inflammatory matrix metalloproteinase-9 is down-regulated, while the T<sub>H</sub>1 marker FMS-like tyrosine kinase 3 ligand increases [<xref ref-type="bibr" rid="B24">24</xref>]. It is likely that a similar mechanism exists in patients with coronary artery disease successfully desensitized to low-dose (81-325 mg/day) aspirin [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec><title>Principles in drug desensitization</title><p>Several cardinal principles in drug desensitization [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B27">27</xref>] for drug allergy/hypersensitivity are as follows:</p><p>
  <list list-type="bullet"><list-item><p>There is no alternative drug available for the treatment of the underlying condition (e.g. allopurinol in chronic tophaceous gout, penicillin in pregnant women with syphilis, platinum salts in recurrent ovarian cancer).</p></list-item><list-item><p>The drugs for the treatment of the underlying condition are superior to the alternatives (e.g. isoniazid for tuberculosis).</p></list-item><list-item><p>The initial reaction should not be potentially life-threatening reaction. Drug induced hypersensitivity syndrome (DiHS), Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) are absolute contraindications to desensitization. However, anaphylaxis is not a contraindication.</p></list-item><list-item><p>The benefits of desensitization outweigh the risks of recurrence of drug hypersensitivity/allergy.</p></list-item><list-item><p>Starting doses are at 1:1,000,000 to 1:100 of the target therapeutic dose depending on the severity of the initial reaction, or based on end-point intradermal skin testing to a non-irritative concentration of the drug.</p></list-item><list-item><p>Dose escalations are doubled at 15-30 min intervals for immediate reactions, or at intervals of up to 24 h for non-immediate reactions.</p></list-item><list-item><p>Close monitoring and resuscitative equipment with staff trained in resuscitation should be available for rapid desensitization.</p></list-item><list-item><p>Pre-medications with systemic corticosteroids or anti-histamines should be avoided.</p></list-item><list-item><p>Concomitant medical conditions should be stable (e.g. asthma, cardiac insufficiency).</p></list-item><list-item><p>The patient is still deemed allergic to the drug to which he/she has been successfully desensitized.</p></list-item><list-item><p>The patient must adhere to the drug daily in order for tolerance to be maintained, unless breakthrough reactions occur where dose escalations may need to be interrupted/slowed down.</p></list-item><list-item><p>In desensitization for non-immediate reactions, periodic monitoring of complete blood count and liver enzymes should be considered prior to interval dose escalations.</p></list-item></list>
  </p><p>The European Academy of Allergy and Clinical Immunology [<xref ref-type="bibr" rid="B4">4</xref>] has recently drawn up guidelines on desensitization in drug allergy. The American Academy of Allergy Asthma and Immunology and the American College of Allergy Asthma and Immunology have also addressed the topic of desensitization or "temporary induction of drug tolerance" in its recent 2010 Updated Practice Parameter on Drug Allergy [<xref ref-type="bibr" rid="B27">27</xref>]. Both academies are in the midst of establishing databases of desensitization protocols for which sufficient evidence for the effectiveness/adverse events for each protocol exists.</p><p>In this review, we will focus on drugs for which desensitization protocols have been described for 4 major classes of diseases highly prevalent in the Asia-Pacific region: infectious, metabolic, cardiovascular diseases and oncological conditions.</p></sec><sec><title>Desensitization for betalactam allergy</title><p>Betalactams are the most common cause of drug allergies in most prospective epidemiological studies on adverse drug reactions/drug allergies [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B32">32</xref>] including studies originating from the Asia-Pacific region [<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>]. The majority of the studies on betalactam desensitization to date have been in patients with cystic fibrosis who require anti-microbial therapy, of which betalactams are the antibiotics of choice [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. Rapid desensitization protocols using oral [<xref ref-type="bibr" rid="B37">37</xref>] and intravenous penicillins, cephalosporins [<xref ref-type="bibr" rid="B38">38</xref>] (ceftriaxone, cefepime [<xref ref-type="bibr" rid="B39">39</xref>], ceftazidime [<xref ref-type="bibr" rid="B40">40</xref>], cefotaxime [<xref ref-type="bibr" rid="B41">41</xref>], and cefazolin [<xref ref-type="bibr" rid="B42">42</xref>]) have been described and in general found to be effective and safe. Successful desensitization protocols to the carbapenems including meropenem [<xref ref-type="bibr" rid="B43">43</xref>] and imipenem/cilastatin [<xref ref-type="bibr" rid="B44">44</xref>] have also been well-described with no adverse reactions, even when used in patients with renal impairment [<xref ref-type="bibr" rid="B45">45</xref>]. Adverse effects where they occur, are usually mild comprising flushing, pruritis, rash or urticaria, with no serious reactions or late reactions in most studies [<xref ref-type="bibr" rid="B46">46</xref>].</p></sec><sec><title>Anti-tuberculous drug desensitization</title><p><italic>Mycobacterium tuberculosis</italic> infection remains endemic in certain parts of Asia, with one-third of the world's burden of TB, or about 4.9 million prevalent cases, found in the World Health Organization South-East Asia Region [<xref ref-type="bibr" rid="B47">47</xref>]. Treatment of TB infection involves combinations of anti-tuberculous drugs including isoniazid, rifampicin, ethambutol and pyrazinamide. Non-immediate reactions to anti-tuberculous drugs are much more common than immediate reactions, with hypersensitivity reactions that lead to discontinuance of antituberculous agents and to switch of therapy seen in 4-5% of the general population [<xref ref-type="bibr" rid="B48">48</xref>]. Drug eruptions in the form of maculopapular eruptions (MPE), lichenoid drug eruptions [<xref ref-type="bibr" rid="B49">49</xref>], haematological reactions, hepatitis, DiHS, SJS/TEN [<xref ref-type="bibr" rid="B50">50</xref>] have all been reported in the literature [<xref ref-type="bibr" rid="B51">51</xref>]. In practice, it is often difficult to determine which of the anti-tuberculous drugs resulted in the allergic drug reaction. Although patch tests and lymphocyte transformation tests would be useful in such situations to help identify the putative drug, these tests are not readily available in the Asia-Pacific region, are often drug- and reaction-specific (hence negative tests may not be useful), and it is usually not possible to defer TB treatment for 4-6 weeks pending the outcome of results of these tests [<xref ref-type="bibr" rid="B52">52</xref>-<xref ref-type="bibr" rid="B55">55</xref>]. Drug provocation tests although useful in helping to determine the putative drug, are not without risks especially in DiHS, SJS and TEN. Second-line drugs like fluoroquinolones, aminoglycosides, cycloserine and clofazamine, are not encouraged as alternative therapy for patients with drug allergy to first-line TB drugs as they are usually reserved for multi-drug-resistant (MDR)-TB [<xref ref-type="bibr" rid="B56">56</xref>]. Even though MDR-TB although only occurs in fewer than 3% of new cases and 18% of re-treatment cases in the south-east Asia region, this still translates to significant absolute numbers of patients [<xref ref-type="bibr" rid="B47">47</xref>]. As such, rapid oral desensitization regimes have been described for streptomycin [<xref ref-type="bibr" rid="B57">57</xref>], isoniazid [<xref ref-type="bibr" rid="B58">58</xref>], rifampicin [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B60">60</xref>], ethambutol [<xref ref-type="bibr" rid="B60">60</xref>], and para-amniosalicylic acid [<xref ref-type="bibr" rid="B61">61</xref>]. These regimes often involve reintroducing the anti-tuberculous drugs as soon as the allergic reaction has settled. In addition, more than one drug often needs to be reintroduced, reaching target dose within 3 days, with at most a 3-5 day interval apart, because leaving patients on anti-tuberculous monotherapy increases the risk of emergence of drug-resistant tuberculosis. If the initial allergic reaction was SJS/TEN, the risks of desensitization versus the benefits would need to be considered very carefully in consultation with the patient, the attending infectious diseases physician or pulmonologist. Most of the published literature on oral desensitization to TB drug therapies in the Asia-Pacific region originates from Japan [<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>] and Korea [<xref ref-type="bibr" rid="B63">63</xref>]. In a series which followed desensitization guidelines of the Japanese Society of Tuberculosis [<xref ref-type="bibr" rid="B62">62</xref>], adverse reactions among 19 patients aged 23-88 years old, included drug eruption (42.1%), drug fever (36.8%), drug fever with drug eruption (15.8%), and drug fever with cervical lymphadenopathy (15.8%). The clinical effect of desensitization therapy for these antituberculous drugs was good in 14/17 (82%) cases for rifampicin, and 6/8 (75%) cases for isoniazid. In another case report from Korea, a child with tuberculous osteomyelitis of the ankle who developed fever, pruritis and hepatitis 3 days after isoniazid, rifampin, kanamycin and pyrazinamide, was successfully desensitized to rifampin, isoniazid and ethambutol with oral steroid and cetirizine after recurrence of skin rash, facial flushing, chest discomfort during the initial desensitization process. She successfully completed the standard isoniazid (10 mg/kg) and rifampin (12 mg/kg) regimens for 18 months without adverse reactions [<xref ref-type="bibr" rid="B63">63</xref>].</p></sec><sec><title>Desensitization in human immunodeficiency virus infection</title><p>Around 4.87 million people are living with HIV in South, East and South-east Asia. The frequency of drug allergy/hypersensitivity among patients with HIV infection ranges from 3-20% [<xref ref-type="bibr" rid="B64">64</xref>]. Before the development of highly active anti-retroviral therapies (HAART), the majority of drug allergies/hypersensitivity were from antimicrobials used for the treatment or prophylaxis of opportunistic infections. These included TMP-SMX, sulfadiazine, dapsone, clindamycin, thiacetazine, aminopenicillins and atovaquone. Adverse reactions ranged from urticaria, maculopapular exanthems to fever, neutropenia, thrombocytopenia, nephritis, elevated liver enzymes, DiHS, SJS and TEN [<xref ref-type="bibr" rid="B65">65</xref>].</p><p>TMP-SMX is used in the treatment and prophylaxis of <italic>Pneumocystis jiroveci</italic> pneumonia and toxoplasmosis. Desensitization protocols have been shown to be useful in Cochrane metaanalyses [<xref ref-type="bibr" rid="B66">66</xref>], and protocols have been developed for use in both adults and children with TMP-SMX allergy. Oral TMP-SMX is usually used, with target doses initially attained within 7 days in the earlier studies [<xref ref-type="bibr" rid="B67">67</xref>], subsequently reduced to 3-days [<xref ref-type="bibr" rid="B68">68</xref>] and 2-days [<xref ref-type="bibr" rid="B69">69</xref>] among adults, then to a 4-hour protocol in infants and children [<xref ref-type="bibr" rid="B70">70</xref>]. Where the initial reaction was SJS/TEN, desensitization has to be carefully discussed with the patient/family as the risks of desensitization may outweigh the benefits [<xref ref-type="bibr" rid="B71">71</xref>]. SMX haptenation, but not SMX-specific antibodies, appear to be important in the development of clinical sensitivity (i.e. failure of desensitization) in patients with AIDS who have undergone SMX desensitization [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>With the introduction of HAART in the 1990s, reports of hypersensitivity reactions to antiretroviral agents have increased. HAART drugs are classified as reverse transcriptase inhibitors (nucleoside [NRTI] and non-nucleoside reverse transcriptase inhibitors [NNRTI]), protease inhibitors (PI), fusion inhibitors, integrase inhibitors and entry inhibitors (CCR5 co-receptor antagonist). Single and various combination (fixed dose) drug therapies are currently available. While most of the anti-retroviral therapies have been associated with drug hypersensitivity/allergy, abacavir (NRTI) and nevirapine (NNRTI) are particularly important as they are associated with potentially serious adverse reactions.</p><p>Abacavir hypersensitivity syndrome is usually multi-organ, potentially life-threatening reaction that occurs in both adults and children and approximately 5% to 8% of HIV-infected treated patients [<xref ref-type="bibr" rid="B72">72</xref>]. HLA-B5701 has been found to be associated with abacavir hypersensitivity among Caucasians [<xref ref-type="bibr" rid="B73">73</xref>] but not in non-Caucasian populations [<xref ref-type="bibr" rid="B74">74</xref>]. Thus, the use of genetic screening prior to prescription of abacavir in Caucasians was the first clinical application of screening of at-risk individuals prior to drug prescription. This originated in Perth, Western Australia which was one of the study sites for the PREDICT-1 study [<xref ref-type="bibr" rid="B75">75</xref>].</p><p>Nevirapine hypersensitivity occurs in 13% [<xref ref-type="bibr" rid="B76">76</xref>], most commonly MPE, with severe cutaneous adverse reactions (SCAR) (including SJS/TEN) occurring in 0.5-1% [<xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B78">78</xref>]. The various types of hypersensitivity/allergy reaction with other anti-retroviral therapies has been comprehensively reviewed elsewhere [<xref ref-type="bibr" rid="B64">64</xref>].</p><p>Single case reports of successful desensitization protocols have been described for amprenavir [<xref ref-type="bibr" rid="B79">79</xref>], darunavir [<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B80">80</xref>], efavirenz [<xref ref-type="bibr" rid="B81">81</xref>], enfuvirtide [<xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B83">83</xref>], nelfinavir [<xref ref-type="bibr" rid="B84">84</xref>] and zidovudine [<xref ref-type="bibr" rid="B85">85</xref>]. As is the case for TB drug allergy, one of the main challenges in HAART drug allergy is the identification of the putative drug: especially since standard therapy often involves 2 NRTIs plus a PI/NNRTI/integrase inhibitor often in addition to antimicrobials for prevention or treatment of opportunistic infections.</p></sec><sec><title>Allopurinol desensitization</title><p>Gout is known to be prevalent in the Asia-Pacific region, ranging from 0.2% in Thailand and Vietnam, to 4% among Australian aboriginals [<xref ref-type="bibr" rid="B86">86</xref>]. Severe tophaceous gout has been described among the Malayo-Polynesian and Malayo-Mongoloid communities in urban and rural North Sulawesi, Indonesia [<xref ref-type="bibr" rid="B87">87</xref>] and Maoris in New Zealand [<xref ref-type="bibr" rid="B88">88</xref>]. Gout is also associated with the metabolic syndrome among Koreans [<xref ref-type="bibr" rid="B89">89</xref>] and Japanese [<xref ref-type="bibr" rid="B90">90</xref>], and an important cause of all-cause and cardiovascular mortality among Taiwanese [<xref ref-type="bibr" rid="B91">91</xref>].</p><p>Allopurinol is a xanthine oxidase inhibitor which is commonly used in the treatment of gout and as prophylaxis against tumor lysis syndrome in the treatment of haematological malignancies. Although 2% of patients administered allopurinol may develop a mild MPE [<xref ref-type="bibr" rid="B92">92</xref>], SJS and TEN are not uncommon [<xref ref-type="bibr" rid="B77">77</xref>]. In Asia, HLA B*5801 has been found to be associated with allopurinol induced SJS/TEN in Han Chinese from studies in Taiwan [<xref ref-type="bibr" rid="B93">93</xref>], Thais [<xref ref-type="bibr" rid="B94">94</xref>], Japanese [<xref ref-type="bibr" rid="B95">95</xref>], and DiHS, SJS/TEN among Koreans [<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>]. However, HLA-A*0201 was not found among Korean patients with SCAR despite relatively high frequency among tolerant controls, suggesting a negative association [<xref ref-type="bibr" rid="B97">97</xref>].</p><p>Allopurinol desensitization was first described by Meyrier in a patient with chronic renal disease [<xref ref-type="bibr" rid="B98">98</xref>]. Subsequent protocols using intraveneous [<xref ref-type="bibr" rid="B99">99</xref>] and oral [<xref ref-type="bibr" rid="B100">100</xref>] formulations have been shown to be generally safe and effective in the long-term [<xref ref-type="bibr" rid="B101">101</xref>]. Cutaneous eruptions are easily managed with temporary withdrawal and dose adjustment of allopurinol, even in individuals with renal impairment [<xref ref-type="bibr" rid="B101">101</xref>]. However, immediate hypersensitivity reactions can recur even after successful desensitization, hence the need for constant vigilance [<xref ref-type="bibr" rid="B102">102</xref>].</p><p>Febuxostat, a selective xanthine oxidase/ xanthine dehydrogenase inhibitor is an alternative treatment for patients who develop adverse reactions to allopurinol [<xref ref-type="bibr" rid="B103">103</xref>]. In the Asia Pacific region where this drug is presently not available, the alternatives for patients with allopurinol allergy who cannot undergo desensitization include [<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B105">105</xref>]:</p><p>
  <list list-type="bullet"><list-item><p>Probenecid, a uricosuric agent, provided renal function is not impaired and the patient does not have urate nephropathy,</p></list-item><list-item><p>Benzbromarone, a uricosuric agent, which is only available in certain countries as it was withdrawn by its original manufacturer in 2003 after reports of serious hepatotoxicty,</p></list-item><list-item><p>Rasburicase, a recombinant urate oxidase which is approved for the prevention and treatment of tumor lysis syndrome in patients receiving chemotherapy for hematologic cancers such as leukemias and lymphomas. Its use in gout remains investigational [<xref ref-type="bibr" rid="B106">106</xref>].</p></list-item></list>
  </p></sec><sec><title>Desensitization to insulins for diabetes mellitus</title><p>The prevalence of diabetes mellitus in Asia Pacific countries ranges from 2.6% to 15.1%, with population attributable fractions ranging from 2% to 12% for coronary heart disease, 1% to 6% for haemorrhagic stroke, and 2% to 11% for ischaemic stroke [<xref ref-type="bibr" rid="B107">107</xref>]. Despite the high prevalence of diabetes mellitus, drug allergy to oral hypoglycemic agents is fortunately uncommon. Case reports of patients with psoriasiform [<xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B109">109</xref>] or lichenoid drug eruptions [<xref ref-type="bibr" rid="B110">110</xref>] to sulfonylureas and biguanide, purpuric dermatoses [<xref ref-type="bibr" rid="B111">111</xref>] and hepatitis [<xref ref-type="bibr" rid="B112">112</xref>] from sulfonylureas, drug-induced hepatitis with thiozolidinediones [<xref ref-type="bibr" rid="B113">113</xref>], and angiotensin-converting enzyme inhibitor angioedema precipitated by dipeptidyl peptidase-IV inhibitors [<xref ref-type="bibr" rid="B114">114</xref>] have been reported.</p><p>Insulin allergy, in the form of localized or systemic reactions which may be immediate, delayed or serum sickness like, occurs in less than 1% of diabetic patients on insulin. It may be due to the insulin itself or its additives (zinc, protamine, cresol, phenol, glycerol). The causative agent can be determined by skin prick and intradermal tests to the insulin preparation, insulin additives; and in specialized centres, measurement of specific IgE or IgG levels to insulin. Insulin allergy is less common these days in view of the use of recombinant insulins [<xref ref-type="bibr" rid="B115">115</xref>]. Nonetheless, diagnostic skin testing and effective desensitization regimes have been well described [<xref ref-type="bibr" rid="B116">116</xref>]. From the Asia-Pacific region, successful desensitization using insulin glargine [<xref ref-type="bibr" rid="B117">117</xref>, <xref ref-type="bibr" rid="B118">118</xref>], crystalline zinc insulin [<xref ref-type="bibr" rid="B119">119</xref>] and continuous insulin infusion [<xref ref-type="bibr" rid="B120">120</xref>] have been reported from Japan and various types of recombinant insulin from Korea [<xref ref-type="bibr" rid="B121">121</xref>-<xref ref-type="bibr" rid="B123">123</xref>]. Human insulin-specific antibody measured 4, 8 and 12 weeks after successful desensitization in a 68-year-old Korean man showed gradual decrease in human insulin specific IgE levels, and increase in IgG1, IgG2 and IgG4 over time [<xref ref-type="bibr" rid="B124">124</xref>]. Recurrence of systemic reaction following successful desensitization to human recombinant insulin has been described in a case report from Singapore [<xref ref-type="bibr" rid="B125">125</xref>].</p></sec><sec><title>ASA desensitization for coronary artery disease</title><p>The incidence of ASA hypersensitivity in the general population ranges from 0.6-2.5% [<xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B127">127</xref>], but that in adult asthmatics ranges from 4.3-11% [<xref ref-type="bibr" rid="B128">128</xref>]. In the Asia-Pacific region, studies from Korea have demonstrated specific genetic and ethnic risk factors in Korean populations for AERD, AIU and AICU [<xref ref-type="bibr" rid="B129">129</xref>]. The true prevalence for ASA hypersensitivity among individuals with coronary artery disease in the Asia-Pacific region is unknown. Nonetheless, low-dose (81-325 mg/day), rapid ASA desensitization-challenge regimes appear to be useful in patients with ASA/NSAID sensitivity with coronary artery disease, in particular those who have undergone percutaneous coronary intervention [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B130">130</xref>]. ASA desensitization is not desensitization in the truest sense of the word as the majority of ASA reactions are largely idiosyncratic with no immune mechanisms involved. The mechanisms are likely to be similar to high-dose ASA desensitization. The published protocols so far have been effective in the majority of patients studied [<xref ref-type="bibr" rid="B131">131</xref>-<xref ref-type="bibr" rid="B133">133</xref>], with relatively low rates of desensitization failure up to 24 months from initiation [<xref ref-type="bibr" rid="B131">131</xref>]. For ASA desensitization failures, alternative types of stents [<xref ref-type="bibr" rid="B134">134</xref>] or other anti-platelet combinations may need to be considered.</p></sec><sec><title>Chemotherapeutic and biologic agents</title><p>Cancer is a major cause of death in the Asia-Pacific with cancer frequencies and cancer types varying across different Asian countries. The incidence and prevalence of gastric cancer is high in East Asia and very low in the South East Asian countries. In contrast, hepatocellular carcinoma rates are high in the entire region in view of the endemicity of chronic hepatitis B infection [<xref ref-type="bibr" rid="B135">135</xref>]. Chemotherapeutic agents that are most commonly associated with hypersensitivity reactions include platinum-based drugs in the treatment of ovarian, small cell lung and germ cell cancer; taxanes and monoclonal antibodies (transtuzumab) used in the treatment of breast cancer; and rituximab in the treatment of non-Hodgkin's lymphoma. These drugs are often needed for refractory or recurrent disease. Standardized 12-step desensitization protocols given intravenously/intraperitoneally over 6 h have been found to be safe and effective in 94% of infusions (mild or no reactions), with no life-threatening adverse reactions reported [<xref ref-type="bibr" rid="B136">136</xref>]. Among patients who received standardized 12-step desensitization protocols for transtuzumab, rituximab and infliximab, hypersensitivity reactions occurred during 29% of desensitizations, including 27 mild reactions, 1 moderate reaction, and 2 severe reactions [<xref ref-type="bibr" rid="B137">137</xref>]. In these studies, the initial desensitizations were done in an intensive care setting, and subsequent infusions as outpatients. Breakthrough symptoms can be managed with anti-histamines and systemic glucocorticoids, and decelerating the dose escalation with intermediate infusion steps [<xref ref-type="bibr" rid="B5">5</xref>].</p></sec></sec><sec><title>CONCLUSION</title><p>The objectives, indications, contraindications, principles of drawing up drug desensitization regimes are similar. However, the mechanisms of desensitization for immediate versus non-immediate reactions are clearly distinct. Most current desensitization regimes are effective and can be safely carry out with careful patient selection and close monitoring under the supervision of trained allergists and nursing staff.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>SG</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Friedmann</surname><given-names>PS</given-names></name><name><surname>Lanier</surname><given-names>BQ</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name><name><surname>Motala</surname><given-names>C</given-names></name><name><surname>Ortega Martell</surname><given-names>JA</given-names></name><name><surname>Platts-Mills</surname><given-names>TA</given-names></name><name><surname>Ring</surname><given-names>J</given-names></name><name><surname>Thien</surname><given-names>F</given-names></name><name><surname>Van Cauwenberge</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>HC</given-names></name></person-group><article-title>Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>113</volume><fpage>832</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">15131563</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thong</surname><given-names>BY</given-names></name><name><surname>Tan</surname><given-names>TC</given-names></name></person-group><article-title>Epidemiology and risk factors for drug allergy</article-title><source>Br J Clin Pharmacol</source><year>2011</year><volume>71</volume><fpage>684</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">21480948</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thong</surname><given-names>BY</given-names></name></person-group><article-title>Update on the management of antibiotic allergy</article-title><source>Allergy Asthma Immunol Res</source><year>2010</year><volume>2</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">20358021</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cernadas</surname><given-names>JR</given-names></name><name><surname>Brockow</surname><given-names>K</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>Aberer</surname><given-names>W</given-names></name><name><surname>Torres</surname><given-names>MJ</given-names></name><name><surname>Bircher</surname><given-names>A</given-names></name><name><surname>Campi</surname><given-names>P</given-names></name><name><surname>Sanz</surname><given-names>ML</given-names></name><name><surname>Castells</surname><given-names>M</given-names></name><name><surname>Demoly</surname><given-names>P</given-names></name><name><surname>Pichler</surname><given-names>WJ</given-names></name></person-group><collab>European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity</collab><article-title>General considerations on rapid desensitization for drug hypersensitivity - a consensus statement</article-title><source>Allergy</source><year>2010</year><volume>65</volume><fpage>1357</fpage><lpage>1366</lpage><pub-id pub-id-type="pmid">20716314</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castells</surname><given-names>M</given-names></name></person-group><article-title>Rapid desensitization for hypersensitivity reactions to medications</article-title><source>Immunol Allergy Clin North Am</source><year>2009</year><volume>29</volume><fpage>585</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">19563999</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberer</surname><given-names>W</given-names></name><name><surname>Bircher</surname><given-names>A</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>Blanca</surname><given-names>M</given-names></name><name><surname>Campi</surname><given-names>P</given-names></name><name><surname>Fernandez</surname><given-names>J</given-names></name><name><surname>Brockow</surname><given-names>K</given-names></name><name><surname>Pichler</surname><given-names>WJ</given-names></name><name><surname>Demoly</surname><given-names>P</given-names></name></person-group><collab>European Network for Drug Allergy (ENDA)</collab><collab>EAACI interest group on drug hypersensitivity</collab><article-title>Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations</article-title><source>Allergy</source><year>2003</year><volume>58</volume><fpage>854</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">12911412</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Kang</surname><given-names>NI</given-names></name><name><surname>Chung</surname><given-names>WC</given-names></name><name><surname>Song</surname><given-names>CH</given-names></name><name><surname>Choi</surname><given-names>IW</given-names></name><name><surname>Choi</surname><given-names>IH</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name></person-group><article-title>Mechanism for acute oral desensitization to antibiotics</article-title><source>Allergy</source><year>2006</year><volume>61</volume><fpage>954</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">16867049</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kepley</surname><given-names>CL</given-names></name></person-group><article-title>Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels</article-title><source>Int Arch Allergy Immunol</source><year>2005</year><volume>138</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">16088210</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odom</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>G</given-names></name><name><surname>Kovarova</surname><given-names>M</given-names></name><name><surname>Furumoto</surname><given-names>Y</given-names></name><name><surname>Ryan</surname><given-names>JJ</given-names></name><name><surname>Wright</surname><given-names>HV</given-names></name><name><surname>Gonzalez-Espinosa</surname><given-names>C</given-names></name><name><surname>Hibbs</surname><given-names>ML</given-names></name><name><surname>Harder</surname><given-names>KW</given-names></name><name><surname>Rivera</surname><given-names>J</given-names></name></person-group><article-title>Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>1491</fpage><lpage>1502</lpage><pub-id pub-id-type="pmid">15173205</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaviya</surname><given-names>R</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Role of STAT6 in IgE receptor/FcepsilonRI-mediated late phase allergic responses of mast cells</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">11751988</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>AR</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Castells</surname><given-names>M</given-names></name></person-group><article-title>Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen</article-title><source>Ann Allergy Asthma Immunol</source><year>2005</year><volume>94</volume><fpage>575</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">15945561</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichler</surname><given-names>WJ</given-names></name></person-group><article-title>Delayed drug hypersensitivity reactions</article-title><source>Ann Intern Med</source><year>2003</year><volume>139</volume><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">14568857</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posadas</surname><given-names>SJ</given-names></name><name><surname>Pichler</surname><given-names>WJ</given-names></name></person-group><article-title>Delayed drug hypersensitivity reactions - new concepts</article-title><source>Clin Exp Allergy</source><year>2007</year><volume>37</volume><fpage>989</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">17581192</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruchalla</surname><given-names>RS</given-names></name><name><surname>Pesenko</surname><given-names>RD</given-names></name><name><surname>Do</surname><given-names>TT</given-names></name><name><surname>Skiest</surname><given-names>DJ</given-names></name></person-group><article-title>Sulfonamide-induced reactions in desensitized patients with AIDS--the role of covalent protein haptenation by sulfamethoxazole</article-title><source>J Allergy Clin Immunol</source><year>1998</year><volume>101</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">9525454</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teraki</surname><given-names>Y</given-names></name><name><surname>Shiohara</surname><given-names>T</given-names></name></person-group><article-title>Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization</article-title><source>Dermatology</source><year>2004</year><volume>209</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15237264</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>C</given-names></name><name><surname>Costello</surname><given-names>J</given-names></name><name><surname>Hodge</surname><given-names>L</given-names></name></person-group><article-title>Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice</article-title><source>BMJ</source><year>2004</year><volume>328</volume><fpage>434</fpage><pub-id pub-id-type="pmid">14976098</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>JR</given-names></name><name><surname>Mathison</surname><given-names>DA</given-names></name><name><surname>Stevenson</surname><given-names>DD</given-names></name></person-group><article-title>Aspirin intolerance in asthma. Detection by oral challenge</article-title><source>J Allergy Clin Immunol</source><year>1972</year><volume>50</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">5073322</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szczeklik</surname><given-names>A</given-names></name><name><surname>Stevenson</surname><given-names>DD</given-names></name></person-group><article-title>Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">12743549</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arm</surname><given-names>JP</given-names></name><name><surname>Austen</surname><given-names>KF</given-names></name></person-group><article-title>Leukotriene receptors and aspirin sensitivity</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1524</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">12421897</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juergens</surname><given-names>UR</given-names></name><name><surname>Christiansen</surname><given-names>SC</given-names></name><name><surname>Stevenson</surname><given-names>DD</given-names></name><name><surname>Zuraw</surname><given-names>BL</given-names></name></person-group><article-title>Inhibition of monocyte leukotriene B<sub>4</sub> production after aspirin desensitization</article-title><source>J Allergy Clin Immunol</source><year>1995</year><volume>96</volume><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">7636051</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasser</surname><given-names>SM</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>GS</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name></person-group><article-title>The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>151</volume><fpage>1326</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">7735581</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>E</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Inhibition of NF-kappa B by sodium salicylate and aspirin</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>956</fpage><lpage>959</lpage><pub-id pub-id-type="pmid">8052854</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-G</surname><given-names>M</given-names></name><name><surname>Melo</surname><given-names>M</given-names></name><name><surname>Keegan</surname><given-names>AD</given-names></name><name><surname>Zamorano</surname><given-names>J</given-names></name></person-group><article-title>Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>1428</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">11801685</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katial</surname><given-names>RK</given-names></name><name><surname>Strand</surname><given-names>M</given-names></name><name><surname>Prasertsuntarasai</surname><given-names>T</given-names></name><name><surname>Leung</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Alam</surname><given-names>R</given-names></name></person-group><article-title>The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><fpage>738</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">20728206</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollapudi</surname><given-names>RR</given-names></name><name><surname>Teirstein</surname><given-names>PS</given-names></name><name><surname>Stevenson</surname><given-names>DD</given-names></name><name><surname>Simon</surname><given-names>RA</given-names></name></person-group><article-title>Aspirin sensitivity: implications for patients with coronary artery disease</article-title><source>JAMA</source><year>2004</year><volume>292</volume><fpage>3017</fpage><lpage>3023</lpage><pub-id pub-id-type="pmid">15613671</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>NA</given-names></name><name><surname>Schroeder</surname><given-names>WS</given-names></name></person-group><article-title>Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy</article-title><source>Ann Pharmacother</source><year>2007</year><volume>41</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17200429</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><collab>Joint Task Force on Practice Parameters</collab><collab>American Academy of Allergy, Asthma and Immunology</collab><collab>American College of Allergy, Asthma and Immunology</collab><collab>Joint Council of Allergy, Asthma and Immunology</collab><article-title>Drug allergy: an updated practice parameter</article-title><source>Ann Allergy Asthma Immunol</source><year>2010</year><volume>105</volume><fpage>259</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">20934625</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allain</surname><given-names>H</given-names></name><name><surname>Chevrant-Breton</surname><given-names>J</given-names></name><name><surname>Beneton</surname><given-names>C</given-names></name><name><surname>Bousser</surname><given-names>AM</given-names></name><name><surname>Bentue-Ferrer</surname><given-names>D</given-names></name><name><surname>Mazeas</surname><given-names>D</given-names></name><name><surname>Van den Driessche</surname><given-names>J</given-names></name></person-group><article-title>Undesirable dermatologic results of drugs. Result of a drug monitoring survey</article-title><source>Ann Med Interne (Paris)</source><year>1983</year><volume>134</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">6228178</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigby</surname><given-names>M</given-names></name><name><surname>Jick</surname><given-names>S</given-names></name><name><surname>Jick</surname><given-names>H</given-names></name><name><surname>Arndt</surname><given-names>K</given-names></name></person-group><article-title>Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975 to 1982</article-title><source>JAMA</source><year>1986</year><volume>256</volume><fpage>3358</fpage><lpage>3363</lpage><pub-id pub-id-type="pmid">2946876</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Classen</surname><given-names>DC</given-names></name><name><surname>Pestotnik</surname><given-names>SL</given-names></name><name><surname>Evans</surname><given-names>RS</given-names></name><name><surname>Burke</surname><given-names>JP</given-names></name></person-group><article-title>Computerized surveillance of adverse drug events in hospital patients</article-title><source>JAMA</source><year>1991</year><volume>266</volume><fpage>2847</fpage><lpage>2851</lpage><pub-id pub-id-type="pmid">1942452</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rademaker</surname><given-names>M</given-names></name><name><surname>Oakley</surname><given-names>A</given-names></name><name><surname>Duffill</surname><given-names>MB</given-names></name></person-group><article-title>Cutaneous adverse drug reactions in a hospital setting</article-title><source>N Z Med J</source><year>1995</year><volume>108</volume><fpage>165</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">7753511</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>VK</given-names></name><name><surname>Sethuraman</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>B</given-names></name></person-group><article-title>Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India</article-title><source>J Postgrad Med</source><year>2001</year><volume>47</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">11832597</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thong</surname><given-names>BY</given-names></name><name><surname>Leong</surname><given-names>KP</given-names></name><name><surname>Tang</surname><given-names>CY</given-names></name><name><surname>Chng</surname><given-names>HH</given-names></name></person-group><article-title>Drug allergy in a general hospital: results of a novel prospective inpatient reporting system</article-title><source>Ann Allergy Asthma Immunol</source><year>2003</year><volume>90</volume><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">12669899</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>TB</given-names></name><name><surname>Kim</surname><given-names>SL</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>KA</given-names></name><name><surname>Bae</surname><given-names>YJ</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Moon</surname><given-names>HB</given-names></name></person-group><article-title>The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2008</year><volume>17</volume><fpage>919</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">18470952</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrows</surname><given-names>JA</given-names></name><name><surname>Toon</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>SC</given-names></name></person-group><article-title>Antibiotic desensitization in adults with cystic fibrosis</article-title><source>Respirology</source><year>2003</year><volume>8</volume><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">12911831</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turvey</surname><given-names>SE</given-names></name><name><surname>Cronin</surname><given-names>B</given-names></name><name><surname>Arnold</surname><given-names>AD</given-names></name><name><surname>Dioun</surname><given-names>AF</given-names></name></person-group><article-title>Antibiotic desensitization for the allergic patient: 5 years of experience and practice</article-title><source>Ann Allergy Asthma Immunol</source><year>2004</year><volume>92</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">15104194</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>TJ</given-names></name><name><surname>Yecies</surname><given-names>LD</given-names></name><name><surname>Shatz</surname><given-names>GS</given-names></name><name><surname>Parker</surname><given-names>CW</given-names></name><name><surname>Wedner</surname><given-names>HJ</given-names></name></person-group><article-title>Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics</article-title><source>J Allergy Clin Immunol</source><year>1982</year><volume>69</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">7061769</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borish</surname><given-names>L</given-names></name><name><surname>Tamir</surname><given-names>R</given-names></name><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name></person-group><article-title>Intravenous desensitization to beta-lactam antibiotics</article-title><source>J Allergy Clin Immunol</source><year>1987</year><volume>80</volume><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">3040836</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Win</surname><given-names>PH</given-names></name><name><surname>Brown</surname><given-names>H</given-names></name><name><surname>Zankar</surname><given-names>A</given-names></name><name><surname>Ballas</surname><given-names>ZK</given-names></name><name><surname>Hussain</surname><given-names>I</given-names></name></person-group><article-title>Rapid intravenous cephalosporin desensitization</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>116</volume><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">15990801</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosal</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>CJ</given-names></name></person-group><article-title>Intravenous desensitization to ceftazidime in cystic fibrosis patients</article-title><source>J Antimicrob Chemother</source><year>1997</year><volume>39</volume><fpage>556</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">9145836</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papakonstantinou</surname><given-names>G</given-names></name><name><surname>Bogner</surname><given-names>JR</given-names></name><name><surname>Hofmeister</surname><given-names>F</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name></person-group><article-title>Cefotaxime desensitization</article-title><source>Clin Investig</source><year>1993</year><volume>71</volume><fpage>165</fpage><lpage>167</lpage></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poston</surname><given-names>SA</given-names></name><name><surname>Jennings</surname><given-names>HR</given-names></name><name><surname>Poe</surname><given-names>KL</given-names></name></person-group><article-title>Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis</article-title><source>Pharmacotherapy</source><year>2004</year><volume>24</volume><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">15162902</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DL</given-names></name><name><surname>Owens</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Zuckerman</surname><given-names>JB</given-names></name></person-group><article-title>Successful meropenem desensitization in a patient with cystic fibrosis</article-title><source>Ann Pharmacother</source><year>2003</year><volume>37</volume><fpage>1424</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">14519038</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Confino-Cohen</surname><given-names>R</given-names></name><name><surname>Goldberg</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name></person-group><article-title>Prolonged continuous i.v. "desensitization" in Tienam hypersensitivity</article-title><source>Allergy</source><year>1997</year><volume>52</volume><fpage>683</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">9226072</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorman</surname><given-names>SK</given-names></name><name><surname>Zed</surname><given-names>PJ</given-names></name><name><surname>Dhingra</surname><given-names>VK</given-names></name><name><surname>Ronco</surname><given-names>JJ</given-names></name></person-group><article-title>Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia</article-title><source>Ann Pharmacother</source><year>2003</year><volume>37</volume><fpage>513</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">12659606</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castells</surname><given-names>M</given-names></name></person-group><article-title>Desensitization for drug allergy</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2006</year><volume>6</volume><fpage>476</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">17088655</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Wares</surname><given-names>F</given-names></name><name><surname>Sahu</surname><given-names>S</given-names></name></person-group><article-title>Tuberculosis in the WHO South-East Asia Region</article-title><source>Bull World Health Organ</source><year>2010</year><volume>88</volume><fpage>164</fpage><pub-id pub-id-type="pmid">20428378</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forget</surname><given-names>EJ</given-names></name><name><surname>Menzies</surname><given-names>D</given-names></name></person-group><article-title>Adverse reactions to first-line antituberculosis drugs</article-title><source>Expert Opin Drug Saf</source><year>2006</year><volume>5</volume><fpage>231</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">16503745</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name></person-group><article-title>Two patients with isoniazid-induced photosensitive lichenoid eruptions confirmed by photopatch test</article-title><source>Photodermatol Photoimmunol Photomed</source><year>1998</year><volume>14</volume><fpage>77</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">9638730</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leenutaphong</surname><given-names>V</given-names></name><name><surname>Sivayathorn</surname><given-names>A</given-names></name><name><surname>Suthipinittharm</surname><given-names>P</given-names></name><name><surname>Sunthonpalin</surname><given-names>P</given-names></name></person-group><article-title>Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand</article-title><source>Int J Dermatol</source><year>1993</year><volume>32</volume><fpage>428</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">7686537</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuaban</surname><given-names>C</given-names></name><name><surname>Bercion</surname><given-names>R</given-names></name><name><surname>Koulla-Shiro</surname><given-names>S</given-names></name></person-group><article-title>HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon</article-title><source>East Afr Med J</source><year>1997</year><volume>74</volume><fpage>474</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">9487410</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbaud</surname><given-names>A</given-names></name></person-group><article-title>Skin testing in delayed reactions to drugs</article-title><source>Immunol Allergy Clin North Am</source><year>2009</year><volume>29</volume><fpage>517</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">19563995</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbaud</surname><given-names>A</given-names></name><name><surname>Gon&#x000e7;alo</surname><given-names>M</given-names></name><name><surname>Bruynzeel</surname><given-names>D</given-names></name><name><surname>Bircher</surname><given-names>A</given-names></name></person-group><article-title>Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions</article-title><source>Contact Dermatitis</source><year>2001</year><volume>45</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">11846746</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichler</surname><given-names>WJ</given-names></name><name><surname>Tilch</surname><given-names>J</given-names></name></person-group><article-title>The lymphocyte transformation test in the diagnosis of drug hypersensitivity</article-title><source>Allergy</source><year>2004</year><volume>59</volume><fpage>809</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">15230812</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lochmatter</surname><given-names>P</given-names></name><name><surname>Zawodniak</surname><given-names>A</given-names></name><name><surname>Pichler</surname><given-names>WJ</given-names></name></person-group><article-title>In vitro tests in drug hypersensitivity diagnosis</article-title><source>Immunol Allergy Clin North Am</source><year>2009</year><volume>29</volume><fpage>537</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">19563996</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caminero</surname><given-names>JA</given-names></name><name><surname>Sotgiu</surname><given-names>G</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Migliori</surname><given-names>GB</given-names></name></person-group><article-title>Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis</article-title><source>Lancet Infect Dis</source><year>2010</year><volume>10</volume><fpage>621</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">20797644</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levene</surname><given-names>GM</given-names></name><name><surname>Withers</surname><given-names>AF</given-names></name></person-group><article-title>Anaphylaxis to streptomycin and hyposensitization (parasensitization)</article-title><source>Trans St Johns Hosp Dermatol Soc</source><year>1969</year><volume>55</volume><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">5370613</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>CL</given-names></name><name><surname>Malasky</surname><given-names>C</given-names></name><name><surname>Ogunkoya</surname><given-names>A</given-names></name><name><surname>Bielory</surname><given-names>L</given-names></name></person-group><article-title>Rapid oral desensitization to isoniazid and rifampin</article-title><source>Chest</source><year>1990</year><volume>98</volume><fpage>1518</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">2245698</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buergin</surname><given-names>S</given-names></name><name><surname>Scherer</surname><given-names>K</given-names></name><name><surname>H&#x000e4;usermann</surname><given-names>P</given-names></name><name><surname>Bircher</surname><given-names>AJ</given-names></name></person-group><article-title>Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance</article-title><source>Int Arch Allergy Immunol</source><year>2006</year><volume>140</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">16514245</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matz</surname><given-names>J</given-names></name><name><surname>Borish</surname><given-names>LC</given-names></name><name><surname>Routes</surname><given-names>JM</given-names></name><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name></person-group><article-title>Oral desensitization to rifampin and ethambutol in mycobacterial disease</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><fpage>815</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">8118654</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Numata</surname><given-names>I</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Nagasawa</surname><given-names>S</given-names></name><name><surname>Murata</surname><given-names>A</given-names></name><name><surname>Shimoide</surname><given-names>H</given-names></name></person-group><article-title>Desensitization of PAS hypersensitivity with Pascon, a compound of PAS and Scormin</article-title><source>Iryo</source><year>1970</year><volume>24</volume><fpage>567</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">5458296</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobashi</surname><given-names>Y</given-names></name><name><surname>Okimoto</surname><given-names>N</given-names></name><name><surname>Matsushima</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Shishido</surname><given-names>S</given-names></name><name><surname>Kawahara</surname><given-names>S</given-names></name><name><surname>Shigeto</surname><given-names>E</given-names></name><name><surname>Takeyama</surname><given-names>H</given-names></name><name><surname>Kuraoka</surname><given-names>T</given-names></name></person-group><article-title>Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis</article-title><source>Kekkaku</source><year>2000</year><volume>75</volume><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">11201137</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HB</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name></person-group><article-title>Rapid oral desensitization to isoniazid, rifampin, and ethambutol</article-title><source>Allergy</source><year>2003</year><volume>58</volume><fpage>540</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">12757467</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>CM</given-names></name><name><surname>Shearer</surname><given-names>WT</given-names></name></person-group><article-title>Diagnosis and management of HIV drug hypersensitivity</article-title><source>J Allergy Clin Immunol</source><year>2008</year><volume>121</volume><fpage>826</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">18190954</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Volberding</surname><given-names>P</given-names></name><name><surname>Jacobsen</surname><given-names>MA</given-names></name></person-group><article-title>Pathogenesis and management of HIV-associated drug hypersensitivity</article-title><source>AIDS clinical review 1995/1996</source><year>1996</year><publisher-loc>New York</publisher-loc><publisher-name>Marcel Dekker</publisher-name><fpage>65</fpage><lpage>98</lpage></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>WK</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name></person-group><article-title>Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><fpage>CD005646</fpage><pub-id pub-id-type="pmid">17443608</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Absar</surname><given-names>N</given-names></name><name><surname>Daneshvar</surname><given-names>H</given-names></name><name><surname>Beall</surname><given-names>G</given-names></name></person-group><article-title>Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients</article-title><source>J Allergy Clin Immunol</source><year>1994</year><volume>93</volume><fpage>1001</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">8006304</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caumes</surname><given-names>E</given-names></name><name><surname>Guermonprez</surname><given-names>G</given-names></name><name><surname>Lecomte</surname><given-names>C</given-names></name><name><surname>Katlama</surname><given-names>C</given-names></name><name><surname>Bricaire</surname><given-names>F</given-names></name></person-group><article-title>Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus</article-title><source>Arch Dermatol</source><year>1997</year><volume>133</volume><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">9126010</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MT</given-names></name><name><surname>Weiss</surname><given-names>PJ</given-names></name><name><surname>Wallace</surname><given-names>MR</given-names></name></person-group><article-title>Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients</article-title><source>AIDS</source><year>1995</year><volume>9</volume><fpage>573</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">7662195</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palusci</surname><given-names>VJ</given-names></name><name><surname>Kaul</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>RM</given-names></name><name><surname>Haines</surname><given-names>KA</given-names></name><name><surname>Kwittken</surname><given-names>PL</given-names></name></person-group><article-title>Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children</article-title><source>Pediatr Infect Dis J</source><year>1996</year><volume>15</volume><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">8724071</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>R</given-names></name><name><surname>Spelman</surname><given-names>D</given-names></name><name><surname>Czarny</surname><given-names>D</given-names></name><name><surname>O'Hehir</surname><given-names>RE</given-names></name></person-group><article-title>Successful desensitization of two patients who previously developed Stevens-Johnson syndrome while receiving trimethoprim-sulfamethoxazole</article-title><source>Clin Infect Dis</source><year>1997</year><volume>25</volume><fpage>1480</fpage><pub-id pub-id-type="pmid">9431406</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutrell</surname><given-names>AG</given-names></name><name><surname>Hernandez</surname><given-names>JE</given-names></name><name><surname>Fleming</surname><given-names>JW</given-names></name><name><surname>Edwards</surname><given-names>MT</given-names></name><name><surname>Moore</surname><given-names>MA</given-names></name><name><surname>Brothers</surname><given-names>CH</given-names></name><name><surname>Scott</surname><given-names>TR</given-names></name></person-group><article-title>Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir</article-title><source>Ann Pharmacother</source><year>2004</year><volume>38</volume><fpage>2171</fpage><lpage>2172</lpage><pub-id pub-id-type="pmid">15536137</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Nolan</surname><given-names>D</given-names></name><name><surname>Witt</surname><given-names>C</given-names></name><name><surname>Masel</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>AM</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Sayer</surname><given-names>D</given-names></name><name><surname>Castley</surname><given-names>A</given-names></name><name><surname>Mamotte</surname><given-names>C</given-names></name><name><surname>Maxwell</surname><given-names>D</given-names></name><name><surname>James</surname><given-names>I</given-names></name><name><surname>Christiansen</surname><given-names>FT</given-names></name></person-group><article-title>Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>727</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">11888582</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetherington</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>AR</given-names></name><name><surname>Mosteller</surname><given-names>M</given-names></name><name><surname>Shortino</surname><given-names>D</given-names></name><name><surname>Baker</surname><given-names>KL</given-names></name><name><surname>Spreen</surname><given-names>W</given-names></name><name><surname>Lai</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>K</given-names></name><name><surname>Handley</surname><given-names>A</given-names></name><name><surname>Dow</surname><given-names>DJ</given-names></name><name><surname>Fling</surname><given-names>ME</given-names></name><name><surname>Stocum</surname><given-names>M</given-names></name><name><surname>Bowman</surname><given-names>C</given-names></name><name><surname>Thurmond</surname><given-names>LM</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name></person-group><article-title>Genetic variations in HLA-B region and hypersensitivity reactions to abacavir</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1121</fpage><lpage>1122</lpage><pub-id pub-id-type="pmid">11943262</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Carosi</surname><given-names>G</given-names></name><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Workman</surname><given-names>C</given-names></name><name><surname>Tomazic</surname><given-names>J</given-names></name><name><surname>J&#x000e4;gel-Guedes</surname><given-names>E</given-names></name><name><surname>Rugina</surname><given-names>S</given-names></name><name><surname>Kozyrev</surname><given-names>O</given-names></name><name><surname>Cid</surname><given-names>JF</given-names></name><name><surname>Hay</surname><given-names>P</given-names></name><name><surname>Nolan</surname><given-names>D</given-names></name><name><surname>Hughes</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>S</given-names></name><name><surname>Fitch</surname><given-names>N</given-names></name><name><surname>Thorborn</surname><given-names>D</given-names></name><name><surname>Benbow</surname><given-names>A</given-names></name></person-group><collab>PREDICT-1 Study Team</collab><article-title>HLA-B*5701 screening for hypersensitivity to abacavir</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>568</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">18256392</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>RB</given-names></name><name><surname>Robinson</surname><given-names>P</given-names></name><name><surname>Dransfield</surname><given-names>K</given-names></name></person-group><article-title>Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection</article-title><source>Clin Ther</source><year>1998</year><volume>20</volume><fpage>1071</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">9916603</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mockenhaupt</surname><given-names>M</given-names></name><name><surname>Viboud</surname><given-names>C</given-names></name><name><surname>Dunant</surname><given-names>A</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Halevy</surname><given-names>S</given-names></name><name><surname>Bouwes Bavinck</surname><given-names>JN</given-names></name><name><surname>Sidoroff</surname><given-names>A</given-names></name><name><surname>Schneck</surname><given-names>J</given-names></name><name><surname>Roujeau</surname><given-names>JC</given-names></name><name><surname>Flahault</surname><given-names>A</given-names></name></person-group><article-title>Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study</article-title><source>J Invest Dermatol</source><year>2008</year><volume>128</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17805350</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotunda</surname><given-names>A</given-names></name><name><surname>Hirsch</surname><given-names>RJ</given-names></name><name><surname>Scheinfeld</surname><given-names>N</given-names></name><name><surname>Weinberg</surname><given-names>JM</given-names></name></person-group><article-title>Severe cutaneous reactions associated with the use of human immunodeficiency virus medications</article-title><source>Acta Derm Venereol</source><year>2003</year><volume>83</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12636014</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohli-Pamnani</surname><given-names>A</given-names></name><name><surname>Huynh</surname><given-names>P</given-names></name><name><surname>Lobo</surname><given-names>F</given-names></name></person-group><article-title>Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus</article-title><source>Ann Allergy Asthma Immunol</source><year>2006</year><volume>96</volume><fpage>620</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">16680935</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos Bravo</surname><given-names>MC</given-names></name><name><surname>Ocampo Hermida</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez Vilela</surname><given-names>J</given-names></name><name><surname>P&#x000e9;rez Rodr&#x000ed;guez</surname><given-names>MT</given-names></name><name><surname>Gavil&#x000e1;n Montenegro</surname><given-names>MJ</given-names></name><name><surname>Arenas Villarroel</surname><given-names>LJ</given-names></name><name><surname>Miralles Alvarez</surname><given-names>C</given-names></name><name><surname>Rodr&#x000ed;guez Dasilva</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez V&#x000e1;zquez</surname><given-names>C</given-names></name></person-group><article-title>Hypersensitivity reaction to darunavir and desensitization protocol</article-title><source>J Investig Allergol Clin Immunol</source><year>2009</year><volume>19</volume><fpage>250</fpage><lpage>251</lpage></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>EJ</given-names></name><name><surname>Kuriakose</surname><given-names>B</given-names></name><name><surname>Knowles</surname><given-names>SR</given-names></name></person-group><article-title>Efavirenz-induced skin eruption and successful desensitization</article-title><source>Ann Pharmacother</source><year>2002</year><volume>36</volume><fpage>430</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">11895054</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahar</surname><given-names>E</given-names></name><name><surname>Moar</surname><given-names>C</given-names></name><name><surname>Pollack</surname><given-names>S</given-names></name></person-group><article-title>Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction</article-title><source>AIDS</source><year>2005</year><volume>19</volume><fpage>451</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">15750403</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSimone</surname><given-names>JA</given-names></name><name><surname>Ojha</surname><given-names>A</given-names></name><name><surname>Pathak</surname><given-names>R</given-names></name><name><surname>Cohn</surname><given-names>J</given-names></name></person-group><article-title>Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>e110</fpage><lpage>e112</lpage><pub-id pub-id-type="pmid">15546072</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demoly</surname><given-names>P</given-names></name><name><surname>Messaad</surname><given-names>D</given-names></name><name><surname>Trylesinski</surname><given-names>A</given-names></name><name><surname>Faucherre</surname><given-names>V</given-names></name><name><surname>Fabre</surname><given-names>J</given-names></name><name><surname>Reynes</surname><given-names>J</given-names></name><name><surname>Delmas</surname><given-names>C</given-names></name><name><surname>Dohin</surname><given-names>E</given-names></name><name><surname>Godard</surname><given-names>P</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name></person-group><article-title>Nelfinavir-induced urticaria and successful desensitization</article-title><source>J Allergy Clin Immunol</source><year>1998</year><volume>102</volume><fpage>875</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">9819308</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name></person-group><article-title>Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS)</article-title><source>J Allergy Clin Immunol</source><year>1993</year><volume>91</volume><fpage>683</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">8436782</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davatchi</surname><given-names>F</given-names></name></person-group><article-title>Rheumatic diseases in the APLAR region</article-title><source>APLAR J Rheumatol</source><year>2006</year><volume>9</volume><fpage>5</fpage><lpage>10</lpage></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padang</surname><given-names>C</given-names></name><name><surname>Muirden</surname><given-names>KD</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Darmawan</surname><given-names>J</given-names></name><name><surname>Nasution</surname><given-names>AR</given-names></name></person-group><article-title>Characteristics of chronic gout in Northern Sulawesi, Indonesia</article-title><source>J Rheumatol</source><year>2006</year><volume>33</volume><fpage>1813</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">16960942</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemp</surname><given-names>P</given-names></name><name><surname>Stansfield</surname><given-names>SA</given-names></name><name><surname>Castle</surname><given-names>B</given-names></name><name><surname>Robertson</surname><given-names>MC</given-names></name></person-group><article-title>Gout is on the increase in New Zealand</article-title><source>Ann Rheum Dis</source><year>1997</year><volume>56</volume><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9059136</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Choi</surname><given-names>KM</given-names></name><name><surname>Baik</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Choe</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Chung</surname><given-names>WT</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group><article-title>The prevalence of metabolic syndrome in patients with gout: a multicenter study</article-title><source>J Korean Med Sci</source><year>2005</year><volume>20</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">16361817</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inokuchi</surname><given-names>T</given-names></name><name><surname>Tsutsumi</surname><given-names>Z</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Ka</surname><given-names>T</given-names></name><name><surname>Moriwaki</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout</article-title><source>J Clin Rheumatol</source><year>2010</year><volume>16</volume><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">20375819</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>CF</given-names></name><name><surname>See</surname><given-names>LC</given-names></name><name><surname>Luo</surname><given-names>SF</given-names></name><name><surname>Ko</surname><given-names>YS</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Hwang</surname><given-names>JS</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Yu</surname><given-names>KH</given-names></name></person-group><article-title>Gout: an independent risk factor for all-cause and cardiovascular mortality</article-title><source>Rheumatology (Oxford)</source><year>2010</year><volume>49</volume><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">19933595</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname><given-names>GT</given-names></name><name><surname>Lawson</surname><given-names>DH</given-names></name><name><surname>Jick</surname><given-names>H</given-names></name></person-group><article-title>Acute adverse reactions attributed to allopurinol in hospitalised patients</article-title><source>Ann Rheum Dis</source><year>1981</year><volume>40</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">7247470</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>SI</given-names></name><name><surname>Chung</surname><given-names>WH</given-names></name><name><surname>Liou</surname><given-names>LB</given-names></name><name><surname>Chu</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>HP</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Lan</surname><given-names>JL</given-names></name><name><surname>Yang</surname><given-names>LC</given-names></name><name><surname>Hong</surname><given-names>HS</given-names></name><name><surname>Chen</surname><given-names>MJ</given-names></name><name><surname>Lai</surname><given-names>PC</given-names></name><name><surname>Wu</surname><given-names>MS</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>KH</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Fann</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name></person-group><article-title>HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>4134</fpage><lpage>4139</lpage><pub-id pub-id-type="pmid">15743917</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassaneeyakul</surname><given-names>W</given-names></name><name><surname>Jantararoungtong</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>PY</given-names></name><name><surname>Tiamkao</surname><given-names>S</given-names></name><name><surname>Khunarkornsiri</surname><given-names>U</given-names></name><name><surname>Chucherd</surname><given-names>P</given-names></name><name><surname>Konyoung</surname><given-names>P</given-names></name><name><surname>Vannaprasaht</surname><given-names>S</given-names></name><name><surname>Choonhakarn</surname><given-names>C</given-names></name><name><surname>Pisuttimarn</surname><given-names>P</given-names></name><name><surname>Sangviroon</surname><given-names>A</given-names></name><name><surname>Tassaneeyakul</surname><given-names>W</given-names></name></person-group><article-title>Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population</article-title><source>Pharmacogenet Genomics</source><year>2009</year><volume>19</volume><fpage>704</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">19696695</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaniwa</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Aihara</surname><given-names>M</given-names></name><name><surname>Matsunaga</surname><given-names>K</given-names></name><name><surname>Tohkin</surname><given-names>M</given-names></name><name><surname>Kurose</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>J</given-names></name><name><surname>Furuya</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Kinoshita</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Kashiwagi</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Ueta</surname><given-names>M</given-names></name><name><surname>Sotozono</surname><given-names>C</given-names></name><name><surname>Ikezawa</surname><given-names>Z</given-names></name><name><surname>Hasegawa</surname><given-names>R</given-names></name></person-group><collab>JSAR research group</collab><article-title>HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis</article-title><source>Pharmacogenomics</source><year>2008</year><volume>9</volume><fpage>1617</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">19018717</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>JW</given-names></name><name><surname>Song</surname><given-names>WJ</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Joo</surname><given-names>KW</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name><name><surname>Chang</surname><given-names>YS</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Min</surname><given-names>KU</given-names></name><name><surname>Kang</surname><given-names>HR</given-names></name></person-group><article-title>HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency</article-title><source>Nephrol Dial Transplant</source><year>2011</year><month>3</month><day>10</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>HR</given-names></name><name><surname>Jee</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Jung</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name><name><surname>Chang</surname><given-names>YS</given-names></name><name><surname>Chang</surname><given-names>IJ</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Min</surname><given-names>KU</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name></person-group><article-title>Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans</article-title><source>Pharmacogenet Genomics</source><year>2011</year><month>2</month><day>04</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyrier</surname><given-names>A</given-names></name></person-group><article-title>Desensitisation in a patient with chronic renal disease and severe allergy to allopurinol</article-title><source>Br Med J</source><year>1976</year><volume>2</volume><fpage>458</fpage><pub-id pub-id-type="pmid">953607</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walz-LeBlanc</surname><given-names>BA</given-names></name><name><surname>Reynolds</surname><given-names>WJ</given-names></name><name><surname>MacFadden</surname><given-names>DK</given-names></name></person-group><article-title>Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization</article-title><source>Arthritis Rheum</source><year>1991</year><volume>34</volume><fpage>1329</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">1930322</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fam</surname><given-names>AG</given-names></name><name><surname>Lewtas</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Paton</surname><given-names>TW</given-names></name></person-group><article-title>Desensitization to allopurinol in patients with gout and cutaneous reactions</article-title><source>Am J Med</source><year>1992</year><volume>93</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">1388001</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fam</surname><given-names>AG</given-names></name><name><surname>Dunne</surname><given-names>SM</given-names></name><name><surname>Iazzetta</surname><given-names>J</given-names></name><name><surname>Paton</surname><given-names>TW</given-names></name></person-group><article-title>Efficacy and safety of desensitization to allopurinol following cutaneous reactions</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">11212165</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unsworth</surname><given-names>J</given-names></name><name><surname>Blake</surname><given-names>DR</given-names></name><name><surname>d'Assis Fonseca</surname><given-names>AE</given-names></name><name><surname>Beswick</surname><given-names>DT</given-names></name></person-group><article-title>Desensitisation to allopurinol: a cautionary tale</article-title><source>Ann Rheum Dis</source><year>1987</year><volume>46</volume><fpage>646</fpage><pub-id pub-id-type="pmid">3662656</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>TL</given-names></name><name><surname>Richette</surname><given-names>P</given-names></name><name><surname>Perez-Ruiz</surname><given-names>F</given-names></name><name><surname>Tausche</surname><given-names>AK</given-names></name><name><surname>Guerne</surname><given-names>PA</given-names></name><name><surname>Punzi</surname><given-names>L</given-names></name><name><surname>Leeb</surname><given-names>B</given-names></name><name><surname>Barskova</surname><given-names>V</given-names></name><name><surname>Uhlig</surname><given-names>T</given-names></name><name><surname>Piment&#x000e3;o</surname><given-names>J</given-names></name><name><surname>Zimmermann-G&#x000f3;rska</surname><given-names>I</given-names></name><name><surname>Pascual</surname><given-names>E</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name></person-group><article-title>International position paper on febuxostat</article-title><source>Clin Rheumatol</source><year>2010</year><volume>29</volume><fpage>835</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">20401506</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name><name><surname>Pascual</surname><given-names>E</given-names></name><name><surname>Barskova</surname><given-names>V</given-names></name><name><surname>Conaghan</surname><given-names>P</given-names></name><name><surname>Gerster</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>J</given-names></name><name><surname>Leeb</surname><given-names>B</given-names></name><name><surname>Liot&#x000e9;</surname><given-names>F</given-names></name><name><surname>McCarthy</surname><given-names>G</given-names></name><name><surname>Netter</surname><given-names>P</given-names></name><name><surname>Nuki</surname><given-names>G</given-names></name><name><surname>Perez-Ruiz</surname><given-names>F</given-names></name><name><surname>Pignone</surname><given-names>A</given-names></name><name><surname>Piment&#x000e4;o</surname><given-names>J</given-names></name><name><surname>Punzi</surname><given-names>L</given-names></name><name><surname>Roddy</surname><given-names>E</given-names></name><name><surname>Uhlig</surname><given-names>T</given-names></name><name><surname>Zimmermann-G&#x000f2;rska</surname><given-names>I</given-names></name></person-group><collab>EULAR Standing Committee for International Clinical Studies Including Therapeutics</collab><article-title>EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>1312</fpage><lpage>1324</lpage><pub-id pub-id-type="pmid">16707532</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>KM</given-names></name><name><surname>Cameron</surname><given-names>JS</given-names></name><name><surname>Snaith</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Seckl</surname><given-names>J</given-names></name><name><surname>Hingorani</surname><given-names>A</given-names></name><name><surname>Jaques</surname><given-names>R</given-names></name><name><surname>Nuki</surname><given-names>G</given-names></name></person-group><collab>British Society for Rheumatology and British Health Professionals in Rheumatology Standards</collab><collab>Guidelines and Audit Working Group (SGAWG)</collab><article-title>British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout</article-title><source>Rheumatology (Oxford)</source><year>2007</year><volume>46</volume><fpage>1372</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">17522099</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cammalleri</surname><given-names>L</given-names></name><name><surname>Malaguarnera</surname><given-names>M</given-names></name></person-group><article-title>Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout</article-title><source>Int J Med Sci</source><year>2007</year><volume>4</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17396159</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Huxley</surname><given-names>RR</given-names></name><name><surname>Lam</surname><given-names>TH</given-names></name><name><surname>Martiniuk</surname><given-names>AL</given-names></name><name><surname>Ueshema</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>WH</given-names></name><name><surname>Welborn</surname><given-names>T</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name></person-group><collab>Asia Pacific Cohort Studies Collaboration</collab><article-title>Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions</article-title><source>Asia Pac J Clin Nutr</source><year>2007</year><volume>16</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">17215197</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goh</surname><given-names>CL</given-names></name></person-group><article-title>Psoriasiform drug eruption due to glibenclamide</article-title><source>Australas J Dermatol</source><year>1987</year><volume>28</volume><fpage>30</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">3122716</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koca</surname><given-names>R</given-names></name><name><surname>Altinyazar</surname><given-names>HC</given-names></name><name><surname>Yenid&#x000fc;nya</surname><given-names>S</given-names></name><name><surname>Tekin</surname><given-names>NS</given-names></name></person-group><article-title>Psoriasiform drug eruption associated with metformin hydrochloride: a case report</article-title><source>Dermatol Online J</source><year>2003</year><volume>9</volume><fpage>11</fpage><pub-id pub-id-type="pmid">12952758</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>GN</given-names></name><name><surname>Harrell</surname><given-names>CC</given-names></name><name><surname>Mehregan</surname><given-names>DR</given-names></name></person-group><article-title>Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature</article-title><source>Cutis</source><year>2005</year><volume>76</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16144288</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>BB</given-names></name><name><surname>Gadenne</surname><given-names>AS</given-names></name></person-group><article-title>Glipizide-induced pigmented purpuric dermatosis</article-title><source>J Am Acad Dermatol</source><year>1999</year><volume>41</volume><fpage>827</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">10534660</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitturi</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>V</given-names></name><name><surname>Kench</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><article-title>Gliclazide-induced acute hepatitis with hypersensitivity features</article-title><source>Dig Dis Sci</source><year>2002</year><volume>47</volume><fpage>1107</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">12018908</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>EJ</given-names></name><name><surname>Davern</surname><given-names>TJ</given-names></name><name><surname>Shakil</surname><given-names>AO</given-names></name><name><surname>Shick</surname><given-names>L</given-names></name><name><surname>Masharani</surname><given-names>U</given-names></name><name><surname>Chow</surname><given-names>H</given-names></name><name><surname>Freise</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>WM</given-names></name><name><surname>Bass</surname><given-names>NM</given-names></name></person-group><collab>Acute Liver Failure Study Group</collab><article-title>Troglitazone-induced fulminant hepatic failure</article-title><source>Dig Dis Sci</source><year>2000</year><volume>45</volume><fpage>549</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">10749332</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>NJ</given-names></name><name><surname>Byiers</surname><given-names>S</given-names></name><name><surname>Carr</surname><given-names>D</given-names></name><name><surname>Maldonado</surname><given-names>M</given-names></name><name><surname>Warner</surname><given-names>BA</given-names></name></person-group><article-title>Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema</article-title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>516</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">19581505</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinzerling</surname><given-names>L</given-names></name><name><surname>Raile</surname><given-names>K</given-names></name><name><surname>Rochlitz</surname><given-names>H</given-names></name><name><surname>Zuberbier</surname><given-names>T</given-names></name><name><surname>Worm</surname><given-names>M</given-names></name></person-group><article-title>Insulin allergy: clinical manifestations and management strategies</article-title><source>Allergy</source><year>2008</year><volume>63</volume><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">18186805</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattson</surname><given-names>JR</given-names></name><name><surname>Patterson</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name></person-group><article-title>Insulin therapy in patients with systemic insulin allergy</article-title><source>Arch Intern Med</source><year>1975</year><volume>135</volume><fpage>818</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">1130927</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuboi</surname><given-names>M</given-names></name><name><surname>Tsuchiya</surname><given-names>T</given-names></name><name><surname>Taguchi</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Iwasaki</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Kakizaki</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, glargine</article-title><source>Nippon Naika Gakkai Zasshi</source><year>2010</year><volume>99</volume><fpage>133</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">20196485</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Izumida</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Osuga</surname><given-names>J</given-names></name><name><surname>Tobe</surname><given-names>K</given-names></name><name><surname>Tsukamoto</surname><given-names>K</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>Successful desensitization by glargine administration in a patient with insulin allergy: a case report</article-title><source>Diabetes Res Clin Pract</source><year>2009</year><volume>84</volume><fpage>e48</fpage><lpage>e49</lpage><pub-id pub-id-type="pmid">19286270</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Koyama</surname><given-names>H</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name><name><surname>Nishizawa</surname><given-names>Y</given-names></name></person-group><article-title>Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering</article-title><source>Diabetes Res Clin Pract</source><year>2003</year><volume>61</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">12965105</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Tomizawa</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion</article-title><source>Intern Med</source><year>1997</year><volume>36</volume><fpage>575</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">9260776</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Lee</surname><given-names>AY</given-names></name></person-group><article-title>Successful desensitization of a case of anaphylaxis to insulin</article-title><source>Korean J Dermatol</source><year>1998</year><volume>36</volume><fpage>1146</fpage><lpage>1148</lpage></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Jang</surname><given-names>CS</given-names></name><name><surname>Whan</surname><given-names>CC</given-names></name><name><surname>Hong</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>JS</given-names></name><name><surname>Choi</surname><given-names>SW</given-names></name></person-group><article-title>A case of anaphylaxis to human recombinant insulin treated by desensitization</article-title><source>Korean J Med</source><year>2002</year><volume>62</volume><fpage>204</fpage><lpage>208</lpage></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>DP</given-names></name><name><surname>Ko</surname><given-names>BS</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name></person-group><article-title>Maintenance of insulin therapy by desensitization in insulin allergy patient</article-title><source>Korean Diabetes J</source><year>2008</year><volume>32</volume><fpage>529</fpage><lpage>531</lpage></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>BK</given-names></name><name><surname>Kang</surname><given-names>MK</given-names></name><name><surname>Kwon</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Jung</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name><name><surname>Kang</surname><given-names>HR</given-names></name><name><surname>Chang</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Min</surname><given-names>KU</given-names></name><name><surname>Kim</surname><given-names>YY</given-names></name></person-group><article-title>A case of change of insulin-specific antibodies following desensitization in insulin hypersensitivity patients</article-title><source>Korean J Asthma Allergy Clin Immunol</source><year>2010</year><volume>30</volume><fpage>63</fpage><lpage>67</lpage></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chng</surname><given-names>HH</given-names></name><name><surname>Leong</surname><given-names>KP</given-names></name><name><surname>Loh</surname><given-names>KC</given-names></name></person-group><article-title>Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization</article-title><source>Allergy</source><year>1995</year><volume>50</volume><fpage>984</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">8834829</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedman</surname><given-names>J</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Poussa</surname><given-names>T</given-names></name><name><surname>Nieminen</surname><given-names>MM</given-names></name></person-group><article-title>Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary diseas e in a population-based study</article-title><source>Int J Epidemiol</source><year>1999</year><volume>28</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">10480701</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasper</surname><given-names>L</given-names></name><name><surname>Sladek</surname><given-names>K</given-names></name><name><surname>Duplaga</surname><given-names>M</given-names></name><name><surname>Bochenek</surname><given-names>G</given-names></name><name><surname>Liebhart</surname><given-names>J</given-names></name><name><surname>Gladysz</surname><given-names>U</given-names></name><name><surname>Malolepszy</surname><given-names>J</given-names></name><name><surname>Szczeklik</surname><given-names>A</given-names></name></person-group><article-title>Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland</article-title><source>Allergy</source><year>2003</year><volume>58</volume><fpage>1064</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">14510727</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vally</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>ML</given-names></name><name><surname>Thompson</surname><given-names>PJ</given-names></name></person-group><article-title>The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients</article-title><source>Thorax</source><year>2002</year><volume>57</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">12096197</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Ye</surname><given-names>YM</given-names></name><name><surname>Palikhe</surname><given-names>NS</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name></person-group><article-title>Genetic and ethnic risk factors associated with drug hypersensitivity</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2010</year><volume>10</volume><fpage>280</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">20485159</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaar</surname><given-names>O</given-names></name><name><surname>Klimek</surname><given-names>L</given-names></name></person-group><article-title>Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2006</year><volume>6</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">16670507</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>JT</given-names></name><name><surname>Nagy</surname><given-names>CS</given-names></name><name><surname>Krinzman</surname><given-names>SJ</given-names></name><name><surname>Maclean</surname><given-names>JA</given-names></name><name><surname>Bloch</surname><given-names>KJ</given-names></name></person-group><article-title>Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema</article-title><source>J Allergy Clin Immunol</source><year>2000</year><volume>105</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">10808182</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberman</surname><given-names>S</given-names></name><name><surname>Neukirch-Stoop</surname><given-names>C</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name></person-group><article-title>Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><fpage>509</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">15695141</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>R</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Musumeci</surname><given-names>G</given-names></name><name><surname>Scuri</surname><given-names>P</given-names></name><name><surname>Invernizzi</surname><given-names>P</given-names></name><name><surname>Bass</surname><given-names>TA</given-names></name><name><surname>Mihalcsik</surname><given-names>L</given-names></name><name><surname>Gavazzi</surname><given-names>A</given-names></name></person-group><article-title>Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation</article-title><source>Am J Cardiol</source><year>2008</year><volume>101</volume><fpage>786</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">18328841</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jim</surname><given-names>MH</given-names></name><name><surname>Yung</surname><given-names>AS</given-names></name><name><surname>Tang</surname><given-names>GK</given-names></name><name><surname>Fan</surname><given-names>KY</given-names></name><name><surname>Chow</surname><given-names>WH</given-names></name></person-group><article-title>Successful use of endothelial progenitor cell capture stents in a coronary artery disease patient with aspirin hypersensitivity who failed initial aspirin desensitization</article-title><source>Int J Cardiol</source><year>2010</year><month>6</month><day>08</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>KY</given-names></name></person-group><article-title>Cancer prevention in the Asia Pacific region</article-title><source>Asian Pac J Cancer Prev</source><year>2010</year><volume>11</volume><fpage>839</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">21133587</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castells</surname><given-names>MC</given-names></name><name><surname>Tennant</surname><given-names>NM</given-names></name><name><surname>Sloane</surname><given-names>DE</given-names></name><name><surname>Hsu</surname><given-names>FI</given-names></name><name><surname>Barrett</surname><given-names>NA</given-names></name><name><surname>Hong</surname><given-names>DI</given-names></name><name><surname>Laidlaw</surname><given-names>TM</given-names></name><name><surname>Legere</surname><given-names>HJ</given-names></name><name><surname>Nallamshetty</surname><given-names>SN</given-names></name><name><surname>Palis</surname><given-names>RI</given-names></name><name><surname>Rao</surname><given-names>JJ</given-names></name><name><surname>Berlin</surname><given-names>ST</given-names></name><name><surname>Campos</surname><given-names>SM</given-names></name><name><surname>Matulonis</surname><given-names>UA</given-names></name></person-group><article-title>Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases</article-title><source>J Allergy Clin Immunol</source><year>2008</year><volume>122</volume><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">18502492</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>PJ</given-names></name><name><surname>Rodriguez Bouza</surname><given-names>T</given-names></name><name><surname>Hsu</surname><given-names>FI</given-names></name><name><surname>Sloane</surname><given-names>DE</given-names></name><name><surname>Castells</surname><given-names>MC</given-names></name></person-group><article-title>Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment</article-title><source>J Allergy Clin Immunol</source><year>2009</year><volume>124</volume><fpage>1259</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">19910036</pub-id></element-citation></ref></ref-list></back></article>